Selected research
Industry Research
SGLT2 Inhibitors Industry Research Report 2026
Market perspective
The global SGLT2 Inhibitors market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for SGLT2 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for SGLT2 Inhibitors is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for SGLT2 Inhibitors is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of SGLT2 Inhibitors include Chia Tai-Tianqing Pharmaceutical, Sandoz, Johnson and Johnson, Merck, Kelun Pharmaceutical, Hengrui Medicine, Hansoh Pharmaceutical Group, Boehringer Ingelheim and Bristol-Myers Squibb, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global SGLT2 Inhibitors market in terms of revenue (US$ million) and, where applicable, sales volume (Pcs), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Pcs) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
SGLT2 Inhibitors Market by Company
Chia Tai-Tianqing Pharmaceutical
Sandoz
Johnson and Johnson
Merck
Kelun Pharmaceutical
Hengrui Medicine
Hansoh Pharmaceutical Group
Boehringer Ingelheim
Bristol-Myers Squibb
AstraZeneca
Starpharma
Orifarm
SGLT2 Inhibitors Segment by Type
Dapagliflozin
Canagliflozin
Canagliflozin
Other
SGLT2 Inhibitors Segment by Application
Single Drug
Combination Medication
SGLT2 Inhibitors Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global SGLT2 Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of SGLT2 Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of SGLT2 Inhibitors.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of SGLT2 Inhibitors manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of SGLT2 Inhibitors by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of SGLT2 Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Dapagliflozin
- Canagliflozin
- Canagliflozin
- Other
Applications
- Single Drug
- Combination Medication
Companies covered
- Chia Tai-Tianqing Pharmaceutical
- Sandoz
- Johnson and Johnson
- Merck
- Kelun Pharmaceutical
- Hengrui Medicine
- Hansoh Pharmaceutical Group
- Boehringer Ingelheim
- Bristol-Myers Squibb
- AstraZeneca
- Starpharma
- Orifarm
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global SGLT2 Inhibitors Market Size (2021-2032)
- 2.2.2 Global SGLT2 Inhibitors Sales (2021-2032)
- 2.2.3 Global SGLT2 Inhibitors Market Average Price (2021-2032)
- 2.3 SGLT2 Inhibitors by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Dapagliflozin
- 2.3.3 Canagliflozin
- 2.3.4 Canagliflozin
- 2.3.5 Other
- 2.4 SGLT2 Inhibitors by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Single Drug
- 2.4.3 Combination Medication
3 Market Competitive Landscape by Manufacturers
- 3.1 Global SGLT2 Inhibitors Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global SGLT2 Inhibitors Sales (Pcs) of Manufacturers (2021-2026)
- 3.3 Global SGLT2 Inhibitors Revenue of Manufacturers (2021-2026)
- 3.4 Global SGLT2 Inhibitors Average Price by Manufacturers (2021-2026)
- 3.5 Global SGLT2 Inhibitors Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of SGLT2 Inhibitors, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of SGLT2 Inhibitors, Product Type & Application
- 3.8 Global Manufacturers of SGLT2 Inhibitors, Established Date
- 3.9 Global SGLT2 Inhibitors Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Chia Tai-Tianqing Pharmaceutical
- 4.1.1 Chia Tai-Tianqing Pharmaceutical Company Information
- 4.1.2 Chia Tai-Tianqing Pharmaceutical Business Overview
- 4.1.3 Chia Tai-Tianqing Pharmaceutical SGLT2 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Chia Tai-Tianqing Pharmaceutical SGLT2 Inhibitors Product Portfolio
- 4.1.5 Chia Tai-Tianqing Pharmaceutical Recent Developments
- 4.2 Sandoz
- 4.2.1 Sandoz Company Information
- 4.2.2 Sandoz Business Overview
- 4.2.3 Sandoz SGLT2 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Sandoz SGLT2 Inhibitors Product Portfolio
- 4.2.5 Sandoz Recent Developments
- 4.3 Johnson and Johnson
- 4.3.1 Johnson and Johnson Company Information
- 4.3.2 Johnson and Johnson Business Overview
- 4.3.3 Johnson and Johnson SGLT2 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Johnson and Johnson SGLT2 Inhibitors Product Portfolio
- 4.3.5 Johnson and Johnson Recent Developments
- 4.4 Merck
- 4.4.1 Merck Company Information
- 4.4.2 Merck Business Overview
- 4.4.3 Merck SGLT2 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Merck SGLT2 Inhibitors Product Portfolio
- 4.4.5 Merck Recent Developments
- 4.5 Kelun Pharmaceutical
- 4.5.1 Kelun Pharmaceutical Company Information
- 4.5.2 Kelun Pharmaceutical Business Overview
- 4.5.3 Kelun Pharmaceutical SGLT2 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Kelun Pharmaceutical SGLT2 Inhibitors Product Portfolio
- 4.5.5 Kelun Pharmaceutical Recent Developments
- 4.6 Hengrui Medicine
- 4.6.1 Hengrui Medicine Company Information
- 4.6.2 Hengrui Medicine Business Overview
- 4.6.3 Hengrui Medicine SGLT2 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Hengrui Medicine SGLT2 Inhibitors Product Portfolio
- 4.6.5 Hengrui Medicine Recent Developments
- 4.7 Hansoh Pharmaceutical Group
- 4.7.1 Hansoh Pharmaceutical Group Company Information
- 4.7.2 Hansoh Pharmaceutical Group Business Overview
- 4.7.3 Hansoh Pharmaceutical Group SGLT2 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Hansoh Pharmaceutical Group SGLT2 Inhibitors Product Portfolio
- 4.7.5 Hansoh Pharmaceutical Group Recent Developments
- 4.8 Boehringer Ingelheim
- 4.8.1 Boehringer Ingelheim Company Information
- 4.8.2 Boehringer Ingelheim Business Overview
- 4.8.3 Boehringer Ingelheim SGLT2 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Boehringer Ingelheim SGLT2 Inhibitors Product Portfolio
- 4.8.5 Boehringer Ingelheim Recent Developments
- 4.9 Bristol-Myers Squibb
- 4.9.1 Bristol-Myers Squibb Company Information
- 4.9.2 Bristol-Myers Squibb Business Overview
- 4.9.3 Bristol-Myers Squibb SGLT2 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Bristol-Myers Squibb SGLT2 Inhibitors Product Portfolio
- 4.9.5 Bristol-Myers Squibb Recent Developments
- 4.10 AstraZeneca
- 4.10.1 AstraZeneca Company Information
- 4.10.2 AstraZeneca Business Overview
- 4.10.3 AstraZeneca SGLT2 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 AstraZeneca SGLT2 Inhibitors Product Portfolio
- 4.10.5 AstraZeneca Recent Developments
- 4.11 Starpharma
- 4.11.1 Starpharma Company Information
- 4.11.2 Starpharma Business Overview
- 4.11.3 Starpharma SGLT2 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Starpharma SGLT2 Inhibitors Product Portfolio
- 4.11.5 Starpharma Recent Developments
- 4.12 Orifarm
- 4.12.1 Orifarm Company Information
- 4.12.2 Orifarm Business Overview
- 4.12.3 Orifarm SGLT2 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Orifarm SGLT2 Inhibitors Product Portfolio
- 4.12.5 Orifarm Recent Developments
5 Global SGLT2 Inhibitors Market Scenario by Region
- 5.1 Global SGLT2 Inhibitors Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global SGLT2 Inhibitors Sales by Region: 2021-2032
- 5.2.1 Global SGLT2 Inhibitors Sales by Region: 2021-2026
- 5.2.2 Global SGLT2 Inhibitors Sales by Region: 2027-2032
- 5.3 Global SGLT2 Inhibitors Revenue by Region: 2021-2032
- 5.3.1 Global SGLT2 Inhibitors Revenue by Region: 2021-2026
- 5.3.2 Global SGLT2 Inhibitors Revenue by Region: 2027-2032
- 5.4 North America SGLT2 Inhibitors Market Facts & Figures by Country
- 5.4.1 North America SGLT2 Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America SGLT2 Inhibitors Sales by Country (2021-2032)
- 5.4.3 North America SGLT2 Inhibitors Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe SGLT2 Inhibitors Market Facts & Figures by Country
- 5.5.1 Europe SGLT2 Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe SGLT2 Inhibitors Sales by Country (2021-2032)
- 5.5.3 Europe SGLT2 Inhibitors Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific SGLT2 Inhibitors Market Facts & Figures by Country
- 5.6.1 Asia Pacific SGLT2 Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific SGLT2 Inhibitors Sales by Country (2021-2032)
- 5.6.3 Asia Pacific SGLT2 Inhibitors Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America SGLT2 Inhibitors Market Facts & Figures by Country
- 5.7.1 South America SGLT2 Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America SGLT2 Inhibitors Sales by Country (2021-2032)
- 5.7.3 South America SGLT2 Inhibitors Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa SGLT2 Inhibitors Market Facts & Figures by Country
- 5.8.1 Middle East and Africa SGLT2 Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa SGLT2 Inhibitors Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa SGLT2 Inhibitors Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global SGLT2 Inhibitors Sales by Type (2021-2032)
- 6.1.1 Global SGLT2 Inhibitors Sales by Type (2021-2032) & (Pcs)
- 6.1.2 Global SGLT2 Inhibitors Sales Market Share by Type (2021-2032)
- 6.2 Global SGLT2 Inhibitors Revenue by Type (2021-2032)
- 6.2.1 Global SGLT2 Inhibitors Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global SGLT2 Inhibitors Revenue Market Share by Type (2021-2032)
- 6.3 Global SGLT2 Inhibitors Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global SGLT2 Inhibitors Sales by Application (2021-2032)
- 7.1.1 Global SGLT2 Inhibitors Sales by Application (2021-2032) & (Pcs)
- 7.1.2 Global SGLT2 Inhibitors Sales Market Share by Application (2021-2032)
- 7.2 Global SGLT2 Inhibitors Revenue by Application (2021-2032)
- 7.2.1 Global SGLT2 Inhibitors Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global SGLT2 Inhibitors Revenue Market Share by Application (2021-2032)
- 7.3 Global SGLT2 Inhibitors Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 SGLT2 Inhibitors Value Chain Analysis
- 8.1.1 SGLT2 Inhibitors Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 SGLT2 Inhibitors Production Mode & Process
- 8.2 SGLT2 Inhibitors Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 SGLT2 Inhibitors Distributors
- 8.2.3 SGLT2 Inhibitors Customers
9 Global SGLT2 Inhibitors Analyzing Market Dynamics
- 9.1 SGLT2 Inhibitors Industry Trends
- 9.2 SGLT2 Inhibitors Industry Drivers
- 9.3 SGLT2 Inhibitors Industry Opportunities and Challenges
- 9.4 SGLT2 Inhibitors Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst